Trading will be launched at the Canadian company’s shares for the production of vaccines and veterinary medicines listed by the increase of their capital (4.500) billion shares as of 12/25/2013. It also approved the Authority held on 12.10.2013 the agenda included approval of the financial statements for the fiscal year ended 31/12/2012 and increase the company’s capital from (4.500) billion shares to (5.400) billion shares in accordance with Article (55 / II) and (55 / III).
The launch of trading on the shares of the Canadian company for the production of vaccines and veterinary medicines (before the increase)
- Post author:admin2540
- Post last modified:January 20, 2023
- Post comments:0 Comments